Table 1.
Demographic and laboratory findings of the study population
| Characteristics | CSF (n = 130) | NCF (n = 130) | p |
|---|---|---|---|
| Gender (male), n (%) | 104 (80%) | 73 (56%) | < 0.001 |
| Age (years) | 54.05 ± 9.61 | 54.82 ± 8.78 | 0.501 |
| BMI, kg/m2 | 29.6 ± 3.5 | 28.9 ± 4.1 | 0.425 |
| Smoking, n (%) | 79 (61%) | 36 (28%) | < 0.001 |
| Hypertension, n (%) | 52 (40%) | 57 (44%) | 0.615 |
| Diabetes mellitus, n (%) | 52 (40%) | 37 (29%) | 0.067 |
| Dyslipidemia, n (%) | 76 (59%) | 67 (52%) | 0.319 |
| Haemoglobin, g/dL | 13.9 ± 1.5 | 13.9 ± 1.6 | 0.909 |
| White blood cell count, (× 103/μL) | 8.67 ± 2.09 | 8.10 (1.55) | 0.029 |
| Neutrophil cell count, (× 103/μL) | 5 (1.18) | 4.67 (0.85) | 0.006 |
| Lymphocyte cell count, (× 103/μL) | 2.11 ± 0.54 | 2.30 (0.47) | 0.008 |
| NLR | 2.49 (0.48) | 1.96 (0.55) | < 0.001 |
| Platelet (103/μL) | 277 (58.25) | 251 (38.75) | < 0.001 |
| Mean platelet volume (fL) | 8.43 ± 1.34 | 8.39 (0.63) | 0.857 |
| PLR | 128.39 (32.44) | 106.18 (24.43) | < 0.001 |
| Fasting glucose, mg/dl | 103.50 (15.25) | 108.50 (16.13) | 0.329 |
| Creatinine, mg/dl | 0.80 (0.12) | 0.78 (0.08) | 0.080 |
| LV ejection fraction (%) | 58.6 ± 4.1 | 57.0 ± 2.6 | 0.452 |
| Total cholesterol, mg/dl | 201.22 ± 34.32 | 197.50 (26.13) | 0.411 |
| HDL cholesterol, mg/dl | 38.50 (5.13) | 46 (7.50) | < 0.001 |
| LDL cholesterol, mg/dl | 130.95 ± 29.82 | 121.38 ± 33.53 | 0.016 |
| Triglyceride, mg/dl | 182.50 (58.88) | 150 (50.37) | < 0.001 |
| Non-HDL cholesterol, mg/dl | 162.50 ± 34.39 | 151.74 ± 32.35 | 0.010 |
| Atherogenic index of plazma | 0.70 ± 0.22 | 0.53 ± 0.24 | < 0.001 |
| Castelli’s risk index I | 5.43 ± 1.44 | 4.45 ± 0.98 | < 0.001 |
| Castelli’s risk index II | 3.55 ± 1.13 | 2.74 ± 0.84 | < 0.001 |
| Atherogenic coefficient | 4.43 ± 1.44 | 3.45 ± 0.98 | < 0.001 |
| ACEI/ARB, n (%) | 40 (31%) | 45 (35%) | 0.569 |
| Calcium canal blocker, n (%) | 20 (15%) | 22 (17%) | 0.781 |
| Beta-blocker, n (%) | 35 (27%) | 30 (23%) | 0.432 |
| Antiplatelet, n (%) | 32 (24%) | 25 (19%) | 0.247 |
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, Atherogenic coefficient non-HDL-C /HDL-C, Atherogenic index of plasma log TG/HDL-C, BMI body mass index, Castelli’s risk index I TC/HDL-C, Castelli’s risk index II LDL-C/HDL-C, CSF coronary slow flow, Non-HDLc TC-HDL-C, HDL High-density lipoprotein, LDL Low-density lipoprotein, LV left ventricular, NCF normal coronary flow, NLR neutrophil lymphocyte ratio, PLR platelet lymphocyte ratio. Bold indicates p value < 0.05 was considered significant